AzTrials
AzTrials

Left Main Coronary Artery DiseaseFUNCTION IINCT06053944

Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Left Main Coronary Artery Stenosis

An observational study of Left Main Coronary Artery Disease, run by China National Center for Cardiovascular Diseases at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a prospective, observational, single-center study. The main purpose of this study is to evaluate the diagnostic accuracy of offline computational ultrasonic flow ratio (UFR) in predicting functionally significant left main (LM) coronary stenosis with conventional pressure wire-based fractional flow reserve… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Left Main Coronary Artery Disease
What is being tested?
fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)
How many people
120 participants
Where
1 siteChina
Study dates
18 Oct 2023to 31 Dec 2024
How long will I take part?
5 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients ≥ 18 years of age who will be admitted for coronary angiography and had an indication for FFR measurement at the Fuwai Hospital, Beijing, China, due to stable angina or unstable angina will be consecutively enrolled.

Who may be able to join

  • Stable angina pectoris, unstable angina pectoris, or after the acute phase of myocardial infarction
  • Age ≥18 years
  • Written informed consent
  • Intermediated left main coronary lesions (diameter stenosis of 30%-80% by visual estimation from coronary angiography)

Who cannot join

  • Ineligible for diagnostic IVUS or FFR examination
  • Prior coronary artery bypass grafting of the interrogated vessels
  • Myocardial infarction within 72 h of coronary angiography
  • Severe heart failure
  • Serum creatinine levels >150 umol/L, or glomerular filtration rates <45 ml/ kg/1.73 m2
  • Allergy to the contrast agent or adenosine
Show all 10Show fewer
  • Life expectancy < 2 years
  • Proximal LAD diffuse lesions (diameter stenosis > 50%)
  • IVUS pullback not covering the entire lesion
  • Severe myocardial bridge in the interrogated vessel

Trial locations and contacts

1 site in 1 country.

Jie Qian, MD contact

+8613601396650

qianjfw@163.com

China1 site, 1 recruiting
  • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Select A State, 100037

    Jie Qian, qianjfw@163.com

    Recruiting

Other trials in China

About this study

This is a prospective, observational, single-center study. The main purpose of this study is to evaluate the diagnostic accuracy of offline computational ultrasonic flow ratio (UFR) in predicting functionally significant left main (LM) coronary stenosis with conventional pressure wire-based fractional flow reserve (FFR) as the standard reference. The study will be conducted in Fuwai Hospital, and a total of 120 patients with intermediated left main coronary vessel diameter stenosis ≥30% and ≤80% are planned to be recruited. Participants who meet the inclusion criteria and do not meet the exclusion criteria will undergo intravascular ultrasound (IVUS) followed by FFR examination. IVUS imaging will be sent to an independent core laboratory for UFR calculation. UFR analyses were performed offline in a blinded fashion without awareness of FFR measurement. Using FFR≤0.80 as the gold standard, the sensitivity and specificity of UFR in the functional significance of left main coronary artery stenosis will be analyzed.

Being tested
fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)
Keywords
intravascular ultrasound, ultrasonic flow ratio, fractional flow reserve
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)Diagnostic test

    UFR is a novel IVUS-derived modality for fast computation of FFR without pressure wires and adenosine.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic accuracy of UFR in predicting functionally significant left main coronary stenosis, using FFR as the reference standard

    Diagnostic accuracy is defined as UFFR (≤0.80 or >0.80) to identify hemodynamically-significant left main coronary stenosis with FFR (≤0.80 or >0.80) as the reference standard.

    Measured: Immediately after the procedure

  2. Sensitivity and specificity of UFR in predicting functionally significant left main coronary stenosis, using FFR as the reference standard

    Sensitivity is defined as the proportion of UFR ≤ 0.80 in vessels with hemodynamically-significant stenosis as measured by FFR (FFR ≤ 0.80); specificity is defined as the proportion of UFR > 0.80 in vessels without hemodynamically-significant stenosis as measured by FFR (FFR > 0.80).

    Measured: Immediately after the procedure

Secondary outcomes (2)
  1. Comparison of sensitivity and specificity of UFR and IVUS-derived minimal lumen area (MLA) in predicting functionally significant left main coronary stenosis, using FFR as the reference standard

    Sensitivity is defined as the proportion of UFR ≤ 0.80 in vessels with hemodynamically-significant stenosis as measured by FFR (FFR ≤ 0.80); specificity is defined as the proportion of UFR > 0.80 in vessels without hemodynamically-significant stenosis as measured by FFR (FFR > 0.80).

    Measured: Immediately after the procedure

  2. The AUC of UFR for left main coronary stenosis with FFR as the gold standard

    AUC is defined as the area under the receiver-operating characteristic curve.

    Measured: Immediately after the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Sep 2023
  2. Study start18 Oct 2023
  3. Primary completion31 Dec 2024 (estimated)
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
120 participants (estimated)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT06053944
Sponsor's protocol ID
2022-12M-C&T-B-043
Acronym
FUNCTION II
Status last verified
Sep 2023
First submitted
17 Sep 2023
Last updated
22 Jan 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Left Main Coronary Artery Disease, run by China National Center for Cardiovascular Diseases at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jie Qian, MD (+8613601396650, qianjfw@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic accuracy of UFR in predicting functionally significant left main coronary stenosis, using FFR as the reference standard (time frame: Immediately after the procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in